During RP2, K-HEALTHinAIR has continued advancing its scientific, technological and operational activities aimed at assessing the impact of indoor air quality (IAQ) on health across Europe. Minor delays were encountered, mainly related to ethical approvals, monitoring deployment in some scenarios and the complexity of integrating multi-country datasets; however, overall progress has remained aligned with the project planning.
IAQ monitoring campaigns have been carried out in most targeted environments, including homes, hospitals, schools, offices and other public settings. A harmonised monitoring protocol supported the collection of a wide dataset covering chemical pollutants, particulate matter and biological contaminants. These data have been integrated into a centralised database, enabling initial cross-scenario analyses and comparative assessments of pollutant levels and influencing factors across different indoor environments.
In parallel, data processing and exploratory analyses have progressed, combining continuous monitoring data with campaign-based measurements, building characteristics, ventilation practices and occupant behaviour. Multivariate approaches are being applied to identify key determinants of IAQ and to characterise exposure patterns. Initial analyses of health questionnaires and available clinical data have started, establishing the basis for linking IAQ conditions with respiratory health outcomes, particularly in sensitive population groups. The preliminary identification of IAQ determinants has been completed and will be further refined as additional data become available.
Progress has also been made in the development and validation of user-oriented IAQ monitoring solutions. Low-cost sensors for carbon dioxide, particulate matter and formaldehyde have been evaluated against reference instruments, and calibration functions have been derived. The portable monitoring system has been tested in multiple real-world environments, supporting its use for continuous IAQ assessment. In addition, work on bio-sensing approaches for fungal metabolites has advanced, including nanoparticle functionalisation and initial prototype validation.
The project’s digital infrastructure has evolved towards an operational Open Access Platform. The platform enables sensor registration, data upload, storage and visualisation in compliance with GDPR requirements. Interfaces for external data integration and analytical functionalities are under development, supporting data exchange within the consortium and preparing for future wider use.
Dissemination, communication and exploitation activities have continued throughout the period, strengthening the project’s visibility through digital channels, newsletters and participation in relevant events and conferences. The exploitation strategy is being developed with a focus on the post-project sustainability of the monitoring tools and the digital platform. Gender and ethical aspects remain integrated across project activities.
Overall, the work carried out during the reporting period has consolidated the foundations required for the final phase of the project. The available datasets, validated monitoring solutions and ongoing analyses provide a consistent basis for the synthesis of health-relevant evidence and policy-oriented outcomes in the remaining project duration.
